Utang jangka cendhak marang ekuitas TuHURA Biosciences, Inc. (HURA)

Logo grafis TuHURA Biosciences, Inc. (HURA)

This chart of current TuHURA Biosciences, Inc. (HURA) quotes on GURU.Markets, where the indicator stands at 0.01, reflects volatility driven by the use of AI in vaccine development and reliance on physicians. Financial stability is declining as the costs of testing new agents exceed revenues, although TuHURA Biosciences, Inc. (HURA) is developing its own IFN-g system, creating a unique protected mechanism for combating tumors.

HURA - Rasio utang jangka cendhak marang ekuitas TuHURA Biosciences, Inc. ing rentang 04.07.2022 - 01.11.2026
Produk mawa merek tuhurabio.com

When assessing the margin of safety for TuHURA Biosciences, Inc. (HURA), I focus on the ability of equity to cover peak volumes of short-term liabilities. This metric measures the risk of a liquidity gap by comparing urgent loans against total capital to determine debt sustainability. By analyzing the trend of short-term accounts payable relative to equity, an investor can gauge asset liquidity. This is critical for a company financing complex joint research to combat tumor resistance.

Pesaing TuHURA Biosciences, Inc.

Utang jangka cendhak marang modal ONC|Utang jangka cendhak marang modal Halozyme Corp (HALO)|Utang jangka cendhak marang ekuitas Revolution Medicines RVMD|AAPG: Rasio utang jangka cendhak marang modal|CG Oncology - Utang jangka cendhak marang modal|UroGen Pharma Ltd (URGN) - Rasio utang jangka cendhak marang ekuitas|BCAX: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Personalis Genomics (PSNL)|Utang jangka cendhak marang ekuitas Erasca, Inc.|DCTH: Rasio tanggungan utang jangka cendhak marang modal|Rasio utang jangka cendhak marang ekuitas YMAB (Y-mAbs Therapeutics, Inc.)|AURA (Aura Biosciences Inc) - Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal CADL (Candel Therapeutics, Inc.)|ARAY - Rasio utang jangka cendhak marang ekuitas|SLS: Rasio utang jangka cendhak marang ekuitas|ACTU - Utang jangka cendhak marang modal|Citius Oncology (CTOR) - Utang jangka cendhak marang ekuitas|Protara Therapeutics Inc - Rasio tanggungan utang jangka cendhak marang modal|FATE (Fate Therapeutics Corp) - Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal Aadi Bio WHWK|Rasio utang jangka cendhak marang ekuitas TCRX (TScan Therapeutics)|Rasio silihan jangka cendhak marang modal CSBR|XBiotech - Rasio utang jangka cendhak marang ekuitas|Utang jangka cendhak marang modal CEL-SCI Corp. CVM|OS Therapies Inc - Utang jangka cendhak marang modal|Rasio tanggungan utang jangka cendhak marang modal RADX (Radiopharm Theranostics Ltd)|ARTV (artivabio.com) - Rasio utang jangka cendhak marang ekuitas|Adlai Nortye (ANL) - Utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Veru|TPST: Rasio tanggungan utang jangka cendhak marang modal|Utang jangka cendhak marang modal XLO|Utang jangka cendhak marang modal renovarobio.com (RENB)|Mural Oncology - Rasio utang jangka cendhak marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal KAPA|OnKure - Utang jangka cendhak marang modal|GDTC: Utang jangka cendhak marang ekuitas|CRIS: Utang jangka cendhak marang modal|APLM - Koefisien utang jangka cendhak marang modal|Utang jangka cendhak marang ekuitas Tharimmune, Inc.|Kewajiban jangka cendhak marang modal Advanced Biomed Corp ADVB|Utang jangka cendhak marang ekuitas Genprex (GNPX)|Koefisien utang jangka cendhak marang modal calidibio.com|Utang jangka cendhak marang modal SBFM (Sunshine Biopharma)|XBIO - Rasio utang jangka cendhak marang ekuitas|Salarius Pharmaceuticals - Utang jangka cendhak marang modal|Koefisien utang jangka cendhak marang modal purple-biotech.com PPBT|AONC: Utang jangka cendhak marang modal|Kewajiban jangka cendhak marang modal BeiGene Ltd. (BGNE)|Utang jangka cendhak marang ekuitas Checkpoint Therapeutics, Inc|Rasio utang jangka cendhak marang modal ELEV (Elevation Oncology Inc.)|Utang jangka cendhak marang modal ICAD|Rasio utang jangka cendhak marang ekuitas ikenaoncology.com IKNA|Utang jangka cendhak marang modal NTBL (Notable Labs)|Viracta Therapeutics Inc. (VIRX) - Kewajiban jangka cendhak marang modal|MOR - Utang jangka cendhak marang ekuitas|Koefisien utang jangka cendhak marang modal NAYA Biosciences Corp NAYA|AAPGV (Ascentage Pharma Group) - Rasio utang jangka cendhak marang ekuitas